Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
|
|
- Iris Riley
- 5 years ago
- Views:
Transcription
1 7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter to the editor Thrombosis and Haemostasis ;104(1):
2
3 Timing of NT-pro-BNP in acute PE 149 The purpose of this study was to determine the optimal therapeutic management of patients with acute pulmonary embolism (PE), all patients diagnosed with this disease should be stratified rapidly according to their risk of mortality, starting with assessment of the patients hemodynamic status (1). Hemodynamically unstable patients have a very high risk of dying (30% or more) and therefore, benefit from treatment with thrombolytic drugs, except for those patients with very high bleeding risks (1). Further risk stratification of normotensive patients with PE allows differentiation between patients that might be considered for outpatient therapy, and patients who should be subjected to clinical treatment and surveillance (2). Blood levels of (N-terminal-pro-) brain-type natriuretic peptide, a peptide that is released in reaction to myocyte stress, can aid the physician in the risk stratification of normotensive patients with PE since high concentrations of (NT-pro-) BNP distinguish patients with higher risk of complicated in-hospital course and death from those with low BNP levels (3). Nonetheless, it has been suggested that (NT-pro-) BNP tests can be falsely negative in case of testing very early (< 24 hours) after onset of symptoms (3). This phenomenon can be explained by the low amounts of BNP prohormone that is stored in normal ventricular myocytes. As a consequence, it might take several hours for the plasma natriuretic peptide levels to significantly increase (4). As a consequence, NT-pro-BNP levels may be falsely low in patients who present very early in the course of disease. Therefore, we studied the influence of early presentation of patients with acute PE on NT-pro-BNP levels and the risk for falsely low NT-pro-BNP levels. We report on a post-hoc analysis of a prospective cohort study of consecutive normotensive patients with computed tomography (CT) proven acute PE (5). These patients were followed for 6 weeks for the occurrence of adverse events including all cause mortality, resuscitation after respiratory or cardiac arrest, admittance to intensive care unit, need for mechanical ventilation and administration of inotropic or thrombolytic agents. Blood samples were taken at clinical presentation and stored. After the study period was completed for all included patients, NT-pro-BNP levels were measured using a quantitative immunoassay (Elecsys 2010 analyzer, Roche Diagnostics, Mannheim, Germany) (5). Predefined threshold for elevated NT-pro-BNP levels was > 600 pg/ml. Researchers who measured NT-pro-BNP levels were blinded for the clinical outcome of the patients. In addition, and to evaluate ventricular function, we assessed the right-to-left ventricular dimension ratios (RV/LVratio) in reconstructed 4-chamber (4-CH) CT-views (5). For the present analysis, we determined the univariate associations of NT-pro-BNP levels and several clinical parameters including time from start of the symptoms to presentation to our hospital. Furthermore, we performed multivariate linear regression analysis to identify independent predictors of NT-pro-BNP concentration. In addition, we determined the risk for a low NT-pro-BNP level adjusted for all these latter independent predictors of NT-pro-BNP concentration in patients who presented to our hospital within 24 hours after onset of symptoms. Finally, we assessed the risk of falsely low NT-pro-BNP levels in patients who presented early in
4 the course of disease. This study was approved by the Institutional Review Board of our hospital and all patients provided written informed consent. In total, 113 normotensive patients with acute PE were included in the study (Table 1). Table 1. Demographics of 113 patients diagnosed with acute pulmonary embolism Age (mean ± SD) 56 ±17 Male sex 60 (53) History of venous thrombosis 25 (22) Active malignancy 24 (21) Recent immobilization, surgery or trauma 35 (31) Inpatient 20 (18) COPD 7 (6.2) Left heart failure 5 (4.4) Duration of complaints (hours; median, IQR) 48 (24-132) RV/LV-ratio (median, IQR) 1.0 ( ) Univariate analysis indicated that time from onset of complaints was not associated with NT-pro-BNP concentration, in contrast to age, active malignancy, inpatient status, previously diagnosed COPD, left heart failure and higher RV/LV-ratio (Table 2). Unless otherwise indicated, data are n (%). Chapter After multivariate backward conditional analysis, gender (p=0.012), previously diagnosed COPD (p=0.048), previously diagnosed left heart failure (p=0.043) and increased RV/LV-ratio (p < 0.001) were independently associated with NT-pro-BNP levels, whereas time from onset of symptoms to clinical presentation was not. Adjusted for these latter significant determinants of NT-pro-BNP levels, presentation within 24 hours after onset of symptoms was not associated with an increased risk for low NT-pro-BNP (n = 41; adjusted odds ratio (OR) 1.1, 95% confidence interval (CI) ). This finding was confirmed after performing the same analysis for patients who presented within 12 hours (n = 23; adjusted OR 1.4, 95%CI ) or within 6 hours (n =14; adjusted OR 1.2, 95%CI ) after start of the symptoms. After 6 weeks, 10 patients had reached a clinical endpoint: 5 patients developed respiratory or cardiac arrest after PE of whom 1 was successfully resuscitated, 1 patient received thrombolytic therapy because of a large saddle embolus, 1 had a major bleeding complication and was subsequently admitted to the intensive care unit and 3 patients died of progressive malignancy. Half of these patients presented to our hospital within 24 hours after onset of the symptoms. The first 7 patients all experienced their complications in the first 2 weeks after diagnosis, and all had clearly elevated NT-pro-BNP blood levels (range 1964 to 6540 pg/ml). The latter 3 patients died of cancer after this 2 week period. Two of these patients had elevated NT-pro-BNP levels at diagnosis. The final patient presented to our emergency ward 8 hours after he first noticed symptoms of acute PE, and had a NT-pro-BNP level beneath the predefined threshold at time of presentation (151 pg/ml). This patient died after 39 days of progressive metastatic prostate cancer. The overall risk for PE-related complications after a low NT-pro-BNP level at clinical presentation
5 Timing of NT-pro-BNP in acute PE 151 was 0% (0/81, 95%CI %), and for overall complications regardless of NT-pro-BNP level was 1.2% (1/81, 95%CI ). The risk for PE-related complications after a low NTpro-BNP level within 24 hours of onset of complaints was 0% (0/30, 95%CI ), and for overall complications 3.3% (1/30, 95%CI ). We conclude from this post hoc analysis that NT-pro-BNP levels with a threshold of 600 pg/ml can be used for risk stratification of patients diagnosed with PE, even in case of early presentation in the course of disease. This conclusion is based on 3 observations: 1) the time span between onset of symptoms and clinical presentation was not related to NT-pro-BNP blood levels; 2) we did not find an increased risk for NT-pro-BNP levels below 600 pg/ml in patients who presented to our hospital within 24, 12 or even 6 hours after start of the symptoms; and 3) the risk of PE related and overall complications after a normal NT-pro-BNP within 24 hours after onset of symptoms was very low. The main limitation of these observations was the relatively limited sample size of our study population. The use of prognostic tests in normotensive patients with confirmed PE is still debated, mainly because there is no clinical evidence that altered treatment strategies based on prognostic tests improve the prognosis or more general clinical outcome, i.e. mortality, patient satisfaction or medical costs, of these patients. In addition, it is not known what would be the most optimal test for this purpose. A recent report suggests that NT-pro-BNP might have superior sensitivity and specificity over Troponin levels, D-dimer levels or right ventricular dimension measurements on CT (5). Direct comparison of NT-pro-BNP with clinical scores are however lacking. Table 2. Correlations between NT-pro-BNP concentration and clinical parameters. Medians (interquartile range) of NT-pro- P value BNP concentration or regression coefficient [coefficient of determination(%)]* Age (per year)* (5.1) Sex (male vs. female) 201 (53 490) vs. 268 ( ) 0.24 Active malignancy (yes vs. no) 418 ( ) vs. 181 (45 586) Recent surgery or trauma (yes vs. no) 227 ( ) vs. 224 (58 661) 0.86 Inpatient (yes vs. no) 623 ( ) vs. 201 (45 519) COPD (yes vs. no) 2310 ( ) vs. 205 (48 674) Left heart failure (yes vs. no) 218 ( ) vs. 204 (52 729) Duration of complaints (per hour) (1.0) 0.31 RV/LV-ratio (median, IQR) 0.22 (5.0) * Regression coefficient from linear regression analysis for continuous parameters, medians and interquartile range for bivariate parameters (Mann-Whitney U test).
6 references 1. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur.Heart J Sep;29(18): Aujesky D, Hughes R, Jimenez D. Short-term prognosis of pulmonary embolism. J.Thromb. Haemost Jul;7 Suppl 1: Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and metaanalysis. Am.J.Respir.Crit Care Med Aug 15;178(4): Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, Masuda I, Nakanishi K, Yoshimasa T, Hashimoto Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995 Sep 15;92(6): Klok FA, van der Bijl N, Eikenboom HC, Van Rooden CJ, de Roos A, Kroft LJ, Huisman MV. Comparison of CT assessed right ventricular size and cardiac biomarkers for predicting short-term clinical outcome in normotensive patients suspected of having acute pulmonary embolism. J.Thromb.Haemost Apr;8(4): Chapter 7 152
Chapter 6. F.A. Klok, N. van der Bijl, J. Eikenboom, C.J. van Rooden, A. de Roos, L.J.M. Kroft and M.V. Huisman. Equally contributed
Chapter 6 Comparison of CT assessed right ventricular size and cardiac biomarkers for predicting short term clinical outcome in normotensive patients suspected for having acute pulmonary embolism F.A.
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationBrain-Type Natriuretic Peptide Levels in the Prediction of Adverse Outcome in Patients with Pulmonary Embolism A Systematic Review and Meta-analysis
Brain-Type Natriuretic Peptide Levels in the Prediction of Adverse Outcome in Patients with Pulmonary Embolism A Systematic Review and Meta-analysis Frederikus A. Klok 1 *, Inge C. M. Mos 1 *, and Menno
More informationRISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain
RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain Potential Conflicts of Interest Financial conflicts of
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationUniversity of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem
University of Groningen BNP and NT-proBNP in heart failure Hogenhuis, Jochem IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19768 holds various files of this Leiden University dissertation. Author: Langevelde, Kirsten van Title: Are pulmonary embolism and deep-vein thrombosis
More informationMassive and Submassive Pulmonary Embolism: 2017 Update and Future Directions
Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions Kush R Desai, MD Assistant Professor of Radiology Northwestern University Feinberg School of Medicine Chicago, IL Disclosures
More informationIs it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital
Is it safe to manage pulmonary embolism in Primary Care? Roopen Arya King s College Hospital A few definitions Safe Avoid death, recurrent thrombosis, bleeding Manage Diagnosis + treatment Pulmonary embolism
More informationAge-adjusted hstnt cut-off value for risk stratification of pulmonary embolism
ERJ Express. Published on January 22, 2015 as doi: 10.1183/09031936.00174514 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Age-adjusted hstnt for risk stratification of pulmonary embolism Anja Kaeberich 1,
More informationEenduidige diagnostiek van longembolie: progress after YEARS
Eenduidige diagnostiek van longembolie: progress after YEARS Menno Huisman Department of Thrombosis and Hemostasis Leiden University Medical Center, Leiden, the Netherlands Disclosures MV Huisman None
More informationAcute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model
ERJ Express. Published on May 12, 2016 as doi: 10.1183/13993003.00024-2016 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationCitation for published version (APA): Douma, R. A. (2010). Pulmonary embolism: advances in diagnosis and prognosis
UvA-DARE (Digital Academic Repository) Pulmonary embolism: advances in diagnosis and prognosis Douma, R.A. Link to publication Citation for published version (APA): Douma, R. A. (2010). Pulmonary embolism:
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationRyan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center
Ryan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center The opinions expressed herein are solely those of the author and do not represent the official views of the Department of Defense
More informationPlasma MR-proADM is superior to NTproBNP for all-cause short term mortality prediction in acute pulmonary embolism.
J. Pedowska-Wloszek, M. Kostrubiec, A. Labyk, S. Pacho, O. Dzikowska-Diduch, P. Bienias, B. Lichodziejewska, P. Palczewski, M. Ciurzynski, P. Pruszczyk Plasma MR-proADM is superior to NTproBNP for all-cause
More informationAdjustments in the diagnostic work-up, treatment and prognosis of pulmonary embolism van Es, Josien
UvA-DARE (Digital Academic Repository) Adjustments in the diagnostic work-up, treatment and prognosis of pulmonary embolism van Es, Josien Link to publication Citation for published version (APA): van
More information4/18/2018. Objectives. Background. 1) Compare and contrast the various validated tools for the identification of patients with pulmonary embolism
Pulmonary Embolism: Assessment, risk-stratification, and treatment plan for the outpatient management of low-risk patients Presentation by Joshua T. Wood, PharmD/PGY-1 Resident Providence St. Patrick Hospital;
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationTreatment of venous thromboembolism: focus on patient characteristics and bleeding complications Brekelmans, M.P.A.
UvA-DARE (Digital Academic Repository) Treatment of venous thromboembolism: focus on patient characteristics and bleeding complications Brekelmans, M.P.A. Link to publication Citation for published version
More information*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND
USE OF N-TERMINAL NATRIURETIC PEPTIDE IN A REAL- WORLD SETTING OF PATIENTS ADMITTED WITH ACUTE DYSPNOEA AND THE IMPLICATION FOR TRIAGING PATIENTS IN THE EMERGENCY DEPARTMENT *Christian M. Carlsen, 1 Mette
More informationAcute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
More informationSupplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
More informationManagement of Acute Pulmonary Embolism. Judith Hurdman Consultant Respiratory Physician
Management of Acute Pulmonary Embolism Judith Hurdman Consultant Respiratory Physician Judith.hurdman@sth.nhs.uk Overview Risk Stratification Who can be managed as an outpatient? To thrombolyse or not
More informationManagement of Intermediate-Risk Pulmonary Embolism
Management of Intermediate-Risk Pulmonary Embolism Stavros V. Konstantinides, MD, PhD, FESC Professor, Clinical Trials in Antithrombotic Therapy Center for Thrombosis und Hemostasis, University of Mainz,
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationPulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy
Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE
More informationEpidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment
Update on Pulmonary Embolism Steven M. Dean, DO, FACP, RPVI Program Director- Vascular Medicine Associate Professor of Internal Medicine Division of Cardiovascular Medicine The Ohio State University Keys
More informationChallenges in the management of acute pulmonary embolism
Challenges in the management of acute pulmonary embolism Case: A pregnant woman presenting with clinical suspicion of acute venous thromboembolism: Appropriate diagnostic and therapeutic strategy in pregnancy.
More informationRisk stratification of normotensive pulmonary embolism: prognostic impact of copeptin
ORIGINAL ARTICLE PULMONARY VASCULAR DISEASE Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin Kristian Hellenkamp 1, Johanna Schwung 1, Heidi Rossmann 2, Anja Kaeberich
More informationStatistical analysis plan
Statistical analysis plan Prepared and approved for the BIOMArCS 2 glucose trial by Prof. Dr. Eric Boersma Dr. Victor Umans Dr. Jan Hein Cornel Maarten de Mulder Statistical analysis plan - BIOMArCS 2
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST IDENTIFYING LOW-RISK PULMONARY EMBOLISM CLINICAL SCORES David Jiménez, MD, PhD Respiratory Department Ramón y Cajal Hospital Madrid, Spain Potential Conflicts of Interest
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationIdentification of intermediate-risk patients with acute symptomatic pulmonary embolism
ORIGINAL ARTICLE PULMONARY VASCULAR DISEASES Identification of intermediate-risk patients with acute symptomatic pulmonary embolism Carlo Bova 1, Olivier Sanchez 2,3, Paolo Prandoni 4, Mareike Lankeit
More informationPE is a difficult diagnosis that may be missed because of non-specific clinical presentation.
Pulmonary embolism (PE) is a relatively common cardiovascular emergency. By occluding the pulmonary arterial bed it may lead to acute life-threatening (3% early mortality rate), but potentially reversible
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationDisclosures. Objectives
BRIGHAM AND WOMEN S HOSPITAL Treatment of Massive and Submassive Pulmonary Embolism Gregory Piazza, MD, MS Assistant Professor of Medicine Harvard Medical School Staff Physician, Cardiovascular Division
More informationEpidemiology of Pulmonary Embolism (PE)
Why Treat Submassive PE Abstract: Massive Pulmonary Embolism (PE) requires immediate lifesaving intervention for the patient. For the submassive PE patient, characterized by presence of right ventricular
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationPredictive value of high-sensitivity troponin I and D-dimer assays for adverse outcome in patients with acute pulmonary embolism
586 Predictive value of high-sensitivity troponin I and D-dimer assays for adverse outcome in patients with acute pulmonary embolism THOMAS WALTER 1, PAUL APFALTRER 2, FRANK WEILBACHER 1, MATHIAS MEYER
More informationIntroduction. Key words: cardiac biomarkers; short-term mortality; perioperative risk; non-cardiac surgery; coronary artery disease
ISSN 2466-488X (Online) doi:10.5937/sjait1806117j Original work PREOPERATIVE HIGH-SENSITIVE TROPONIN T AND N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE IN PREDICTION OF SHORT-TERM MORTALITY AFTER NON-CARDIAC
More informationIs Thrombolysis Only for a Crisis?
Is Thrombolysis Only for a Crisis? December 19, 2017 Is Thrombolysis Only for a Crisis? Indications for Thrombolytic Therapy in Patients with Acute Pulmonary Embolism Case Scenario A 28 year old woman
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationChapter 3. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism
Chapter 3 Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism F.A. Klok, I.C.M. Mos, M. Nijkeuter, M. Righini, A. Perrier, G. Le Gal and M.V. Huisman Arch
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationOpen Access Original Article
Open Access Original Article Prognostic role of simplified Pulmonary Embolism Severity Index and the European Society of Cardiology Prognostic Model in short- and long-term risk stratification in pulmonary
More informationOutcome of elderly patients with severe but asymptomatic aortic stenosis
Outcome of elderly patients with severe but asymptomatic aortic stenosis Robert Zilberszac, Harald Gabriel, Gerald Maurer, Raphael Rosenhek Department of Cardiology Medical University of Vienna ESC Congress
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationAge-adjusted vs conventional D-dimer thresholds in the diagnosis of venous thromboembolism
James Madison University JMU Scholarly Commons Physician Assistant Capstones The Graduate School 5-16-2017 Age-adjusted vs conventional D-dimer thresholds in the diagnosis of venous thromboembolism Kirsten
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationHow to Diagnose Pulmonary Embolism anno 2014?
How to Diagnose Pulmonary Embolism anno 2014? Mark H.H. Kramer, MD, PhD, FRCP FACP Professor of Medicine VU University Medical Center Amsterdam, The Netherlands What are we going to discuss? Age adjusted
More informationPaul den Exter for the Vesta Study Investigators
Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without NT-proBNP testing in patients with acute pulmonary embolism: a randomized clinical trial Am J Respir
More informationOptimal Management of Intermediate-Risk Pulmonary Embolism
Optimal Management of Intermediate-Risk Pulmonary Embolism Stavros V. Konstantinides, MD, PhD, FESC Professor, Clinical Trials in Antithrombotic Therapy Center for Thrombosis und Hemostasis, University
More informationcobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care cobas cardio
cobas h 232 system When on the spot cardiac decisions need on the spot results in Primary Care Is there a better pathway? Without Point of Care (POC) testing Patient presents Blood sample taken Lab collects
More informationVenous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic
More informationImplementation and outcomes of point-ofcare testing in the emergency department of a large urban academic medical center
Implementation and outcomes of point-ofcare testing in the emergency department of a large urban academic medical center Kent Lewandrowski, MD Associate Chief Of Pathology, Massachusetts General Hospital
More informationRight ventricular dysfunction (RVD) is a. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction
Eur Respir J 2012; 39: 919 926 DOI: 10.1183/09031936.00088711 CopyrightßERS 2012 Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction T. Henzler*,#,1, S. Roeger
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Clinical and economic effectiveness of an inpatient anticoagulation service Mamdani M M, Racine E, McCreadie S, Zimmerman C, O'Sullivan T L, Jensen G, Ragatzki P, Stevenson J G Record Status This is a
More informationAdjustments in the diagnostic work-up, treatment and prognosis of pulmonary embolism van Es, Josien
UvA-DARE (Digital Academic Repository) Adjustments in the diagnostic work-up, treatment and prognosis of pulmonary embolism van Es, Josien Link to publication Citation for published version (APA): van
More informationImpact of Delay in Clinical Presentation on the Diagnostic Management and Prognosis of Patients with Suspected Pulmonary Embolism
Impact of Delay in Clinical Presentation on the Diagnostic Management and Prognosis of Patients with Suspected Pulmonary Embolism Paul L. den Exter 1 *, Josien van Es 2 *, Petra M. G. Erkens 3, Mark J.
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationCARDIOVASCULAR N-terminal pro-b-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study
CARDIOVASCULAR N-terminal pro-b-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study B. H. Cuthbertson 1 *, B. L. Croal 2, D. Rae 1, P. H. Gibson 3, J. D.
More informationcobas h 232 POC system The power to make decisions in cardiac emergencies
cobas h 232 POC system The power to make decisions in cardiac emergencies cobas h 232 POC system Rapid results at the Point of Care (POC) Wherever and whenever you face an emergency situation, measurement
More informationPulmonary Embolectomy:
Pulmonary Embolectomy: Recommendation for early surgical intervention Tomas A. Salerno, M.D. Professor of Surgery, University of Miami Miller School of Medicine and Jackson Memorial Hospital Epidemiology
More informationPulmonary Embolism Newer Concepts and Role of Thrombolysis
CHAPTER 69 Pulmonary Embolism Newer Concepts and Role of Thrombolysis J. P. S. Sawhney, A. Bakhshi, B. Kandpal Introduction Pulmonary embolism (PE) is a common cardiovascular and cardiopulmonary illness
More informationMAKING THE NSQIP PARTICIPANT USE DATA FILE (PUF) WORK FOR YOU
MAKING THE NSQIP PARTICIPANT USE DATA FILE (PUF) WORK FOR YOU Hani Tamim, PhD Clinical Research Institute Department of Internal Medicine American University of Beirut Medical Center Beirut - Lebanon Participant
More informationSYSTEMATIC REVIEWS OF TEST ACCURACY STUDIES
Biomarker & Test Evaluation Program SYSTEMATIC REVIEWS OF TEST ACCURACY STUDIES Patrick MM Bossuyt Structure 1. Clinical Scenarios 2. Test Accuracy Studies 3. Systematic Reviews 4. Meta-Analysis 5.
More informationHeart Health ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Heart Health Open Access Received: Oct 22, 2014 Accepted: Dec 01, 2014 Published: Dec 05, 2014 http://dx.doi.org/10.14437/hhoa-1-105 Review Jiri Widimsky, Heart Health Open Access 2014, 1:1 2014 ESC Guidelines
More informationChapter 13. Quality of life after pulmonary embolism: validation of the PEmb-QoL questionnaire
Chapter 13 Quality of life after pulmonary embolism: validation of the PEmb-QoL questionnaire F.A. Klok, D.M. Cohn, S. Middeldorp, M. Scharloo, H.R. Büller, K.W. van Kralingen, A.A. Kaptein and M.V. Huisman
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20073 holds various files of this Leiden University dissertation. Author: Zondag, Wendy Title: Pulmonary embolism : outpatient treatment and risk stratification
More informationD-dimer/troponin ratio in the differential diagnosis of acute pulmonary embolism from non-st elevation myocardial infarction
ORIGINAL ARTICLE 2019 Jan 28. [Epub ahead of print] D-dimer/troponin ratio in the differential diagnosis of acute pulmonary embolism from non-st elevation myocardial infarction Jong Yoon Kim 1, Kye Hun
More informationPulmonary embolism (PE) can be considered in patients with a wide
Ruling Out Pulmonary Embolism in Primary Care: Comparison of the Diagnostic Performance of Gestalt and the Wells Rule Janneke M. T. Hendriksen, MD, PhD 1 Wim A. M. Lucassen, MD, PhD 2 Petra M. G. Erkens,
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationImpaired renal function predicts short term prognosis in patients with acute pulmonary embolism
Impaired renal function predicts short term prognosis in patients with acute pulmonary embolism Kostrubiec Maciej, Łabyk Andrzej, Pedowska-Włoszek Jusyna, Pacho Szymon, Jankowski Krzysztof, Koczaj-Bremer
More informationVenous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.
Venous Thrombosis Magnitude of the Problem DVT 2 Million Postthrombotic Syndrome 800,000 PE 600,000 Death 60,000 Silent PE 1 Million Pulmonary Hypertension 30,000 Estimated Cost of VTE Care $1.5 Billion/year
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationEchocardiography and PESI have independent prognostic role in pulmonary embolism
ERJ Express. Published on December 20, 2012 as doi: 10.1183/09031936.00097512 Echocardiography and PESI have independent prognostic role in pulmonary embolism Running head: Risk stratification in pulmonary
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic
More informationCARDIAC PROBLEMS IN PREGNANCY
CARDIAC PROBLEMS IN PREGNANCY LAS VEGAS, NEVADA, USA 27 February 1 March 2016 SUCCESSFUL TREATMENT WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR OF MASSIVE PULMONARY EMBOLISM IN THE 16 TH WEEK OF PREGNANCY
More informationB-type Natriuretic Peptide in VHD: a Non-imaging Helper for the Cardiologist. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM
B-type Natriuretic Peptide in VHD: a Non-imaging Helper for the Cardiologist Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM Conflict of Interest Disclosure None BNP Molecular Forms and Processing Brain
More informationThrombosis Research 129 (2012) Contents lists available at SciVerse ScienceDirect. Thrombosis Research
Thrombosis Research 129 (2012) 710 714 Contents lists available at SciVerse ScienceDirect Thrombosis Research journal homepage: www.elsevier.com/locate/thromres Regular Article Does the Pulmonary Embolism
More informationCardiovascular Images
Cardiovascular Images Pulmonary Embolism Diagnosed From Right Heart Changes Seen After Exercise Stress Echocardiography Brian C. Case, MD; Micheas Zemedkun, MD; Amarin Sangkharat, MD; Allen J. Taylor,
More informationSingle Center 4 year series of 114 consecutive patients treated for massive and submassive PE. Mark Goodwin, MD
Single Center 4 year series of 114 consecutive patients treated for massive and submassive PE Mark Goodwin, MD Disclosure Speaker name:... I have the following potential conflicts of interest to report:
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram Ben-Gal T, Zafrir
More informationCitation for published version (APA): Lok, D. J. A. (2013). Novel markers in chronic heart failure. Groningen: s.n.
University of Groningen Novel markers in chronic heart failure Lok, Dirk Jan Arend IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationThe Pulmonary Embolism Severity Index in Predicting the Prognosis of Patients With Pulmonary Embolism
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.123 The Pulmonary Embolism Severity Index in Predicting the Prognosis of Patients With Pulmonary Embolism Won-Ho Choi 1, Sung Uk Kwon 1,2, Yoon Jung Jwa 1,
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More information